Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 2
1993 1
1994 1
1995 1
1996 1
2000 2
2006 1
2011 1
2017 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.
Konkel MJ, Lagu B, Boteju LW, Jimenez H, Noble S, Walker MW, Chandrasena G, Blackburn TP, Nikam SS, Wright JL, Kornberg BE, Gregory T, Pugsley TA, Akunne H, Zoski K, Wise LD. Konkel MJ, et al. Among authors: boteju lw. J Med Chem. 2006 Jun 29;49(13):3757-8. doi: 10.1021/jm060001n. J Med Chem. 2006. PMID: 16789730
Identification and characterization of two G protein-coupled receptors for neuropeptide FF.
Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP, Raddatz R, Yao WJ, Ogozalek KL, Boyle N, Kouranova EV, Quan Y, Vaysse PJ, Wetzel JM, Branchek TA, Gerald C, Borowsky B. Bonini JA, et al. Among authors: boteju lw. J Biol Chem. 2000 Dec 15;275(50):39324-31. doi: 10.1074/jbc.M004385200. J Biol Chem. 2000. PMID: 11024015 Free article.
Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system.
Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, Zhou S, Kouranova EV, Nagorny R, Guevarra MS, Dai M, Lerman GS, Vaysse PJ, Branchek TA, Gerald C, Forray C, Adham N. Raddatz R, et al. Among authors: boteju lw. J Biol Chem. 2000 Oct 20;275(42):32452-9. doi: 10.1074/jbc.M004613200. J Biol Chem. 2000. PMID: 10899166 Free article.
The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ. Boteju LW, et al. J Med Chem. 1996 Sep 27;39(20):4120-4. doi: 10.1021/jm960078j. J Med Chem. 1996. PMID: 8831778
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Alistar A, et al. Among authors: boteju lw. Lancet Oncol. 2017 Jun;18(6):770-778. doi: 10.1016/S1470-2045(17)30314-5. Epub 2017 May 8. Lancet Oncol. 2017. PMID: 28495639 Free PMC article. Clinical Trial.
12 results